Document:

Exhibit 4.1

    

    

    KADMON HOLDINGS, INC.

    

    

    AND

    

    

    U.S. BANK NATIONAL ASSOCIATION,

    

    

    as Trustee

    

    

    FIRST SUPPLEMENTAL INDENTURE

    

    

    Dated as of November 9, 2021

    

    

    3.625% Convertible Senior Notes due 2027

    

    

    
      

      
        

      

    

    
    

    

    FIRST SUPPLEMENTAL INDENTURE, dated as of November 9, 2021 (this “Supplemental Indenture”), among Kadmon Holdings, Inc., a Delaware corporation (the “Company”), as issuer, and
      U.S. Bank National Association, a national banking association organized under the laws of the United States of America, as trustee (the “Trustee”),
      to the Indenture, dated as of February 16, 2021 (as supplemented or otherwise modified prior to the date hereof, the “Indenture”), between the
      Company and the Trustee.

    

    

    WHEREAS, the Company has heretofore executed and delivered the Indenture, pursuant to which the Company issued its 3.625% Convertible
      Senior Notes due 2027 (the “Notes”) in the original aggregate principal amount of $240,000,000;

    

    

    WHEREAS, the Company has entered into an Agreement and Plan of Merger, dated as of September 7, 2021 (as amended, supplemented, restated or
      otherwise modified, the “Merger Agreement”), by and among the Company, Sanofi, a French société anonyme (the “Parent”), and Latour Merger Sub, Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Parent (“Merger Sub”);

    

    

    WHEREAS, pursuant to the terms of the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”) on the date hereof with the Company, as the surviving entity in the Merger, becoming a wholly owned subsidiary of Parent as of the date hereof;

    

    

    WHEREAS, the Merger constitutes a Common Stock Change Event under the Indenture;

    

    

    WHEREAS, Section 5.09(A) of the Indenture provides that, at or before the effective time of any Common Stock Change Event, the Company and the resulting, surviving or transferee Person (if not the Company) of such Common Stock Change Event will execute and deliver to the Trustee a
      supplemental indenture pursuant to Section 8.01(F) of the Indenture, which supplemental indenture will (x) provide for subsequent conversions of Notes in the manner set
        forth in Section 5.09 of the Indenture; (y) provide for subsequent adjustments to the Conversion Rate pursuant to Section 5.05(A) of the Indenture in a manner consistent with Section 5.09 of the Indenture; and (z) contain such other provisions, if
        any, that the Company reasonably determines are appropriate to preserve the economic interests of the Holders and to give effect to the provisions of Section 5.09(A) of the Indenture;

    

    

    WHEREAS, in connection with the Merger, each outstanding share of Common Stock prior to the effective time (other than certain shares of
      Common Stock as set forth in the Merger Agreement) shall be converted into the right to receive an amount in cash equal to $9.50, without interest, in accordance with the terms of the Merger Agreement;

    

    

    WHEREAS, Section 8.01 of the Indenture provides that the Company and the Trustee may amend or supplement the Indenture without the consent
      of any Holder to, among other things, (i) enter into supplemental indentures pursuant to, and in accordance with, Section 5.09 of the Indenture in connection with a Common Stock Change Event; or (ii) make any change to the Indenture that does not,
      individually or in the aggregate with all other such changes, adversely affect the rights of the Holders, as such, in any material respect;

    

    

    WHEREAS, in connection with the execution and delivery of this Supplemental Indenture, the Trustee has received an Officer’s Certificate
      and an Opinion of Counsel as contemplated by Sections 8.06, 11.02 and 11.03 of the Indenture; and

    

    

    
      

      2

      
        

      

    

    WHEREAS, the Company has requested that the Trustee execute and deliver this Supplemental Indenture and have satisfied all requirements
      necessary to make this Supplemental Indenture a valid instrument in accordance with its terms.

    

    

    WITNESSETH:

    

    

    NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby
      acknowledged, the Company covenants and agrees with the Trustee as follows for the equal and ratable benefit of the Holders:

    

    

    ARTICLE 1

    

    

    DEFINITIONS

    

    

    Section 1.01. Definitions in the
        Supplemental Indenture. Unless otherwise specified herein or the context otherwise requires:

    

    

    (a) a term defined in the Indenture has the same meaning when used in this Supplemental Indenture unless the definition of such term is
      amended or supplemented pursuant to this Supplemental Indenture;

    

    

    (b) the terms defined in this Article and in this Supplemental Indenture include the plural as well as the singular; and

    

    

    (c) unless otherwise stated, a reference to a Section or Article is to a Section or Article of this Supplemental Indenture.

    

    

    ARTICLE 2

    

    

    EFFECT OF MERGER ON CONVERSION

    

    

    Section 2.01. Conversion Right. In
      accordance with and subject to Section 5.09 of the Indenture, from and after the effective time of the Merger, (a) a Reference Property Unit under the Indenture will be comprised of the right to receive an amount in cash equal to $9.50 per share of
      the Company’s common stock; (b) the Conversion Consideration due upon conversion of any Note, and the conditions to any such conversion, will be determined in the same manner as if each reference to any number of shares of Common Stock in Article 5
      of the Indenture (or in any related definitions) were instead a reference to the same number of Reference Property Units; (c) for purposes of Section 4.03 of the Indenture, each reference to any number of shares of Common Stock in such Section (or in
      any related definitions) will instead be deemed to be a reference to the same number of Reference Property Units; (d) the Company will be deemed to elect Physical Settlement in respect of all conversions whose Conversion Date occurs on or after the
      effective date of the Merger and will pay the cash due upon such conversions no later than the fifth (5th) Business Day after the relevant Conversion Date; (e) the Conversion Rate will be adjusted in the same manner as, and at the same time and for
      the same events for which, the Conversion Rate is adjusted pursuant to Section 5.05(A) of the Indenture in a manner consistent with Section 5.09 of the Indenture; and (f)
        the Daily VWAP and Last Reported Sale Price of a Reference Property Unit shall be $9.50.

    

    

    
      

      3

      
        

      

    

    ARTICLE 3

    

    

    MISCELLANEOUS

    

    

    Section 3.01. Ratification of Indenture.
      The Indenture, as supplemented by this Supplemental Indenture, is in all respects ratified and confirmed, and this Supplemental Indenture shall be deemed part of the Indenture in the manner and to the extent herein and therein provided.

    

    

    Section 3.02. Trustee Not Responsible for
        Recitals. The recitals herein contained are made by the Company and not by the Trustee, and the Trustee assumes no responsibility for the correctness thereof. The Trustee makes no representation as to the validity or sufficiency of this
      Supplemental Indenture. All of the provisions contained in the Indenture in respect of the rights, privileges, immunities, powers, and duties of the Trustee shall be applicable in respect of the Supplemental Indenture as fully and with like force and
      effect as though set forth in full herein.

    

    

    Section 3.03 Successors. All agreements of the Company and the Trustee in this Supplemental Indenture will bind their respective successors.

    

    

    Section 3.04. Governing Law. THIS
      SUPPLEMENTAL INDENTURE AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

    

    

    Section 3.05. Headings, Etc. The
      titles and headings of the articles and sections of this Supplemental Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions
      hereof.

    

    

    Section 3.06. Execution in Counterparts.
      This Supplemental Indenture may be executed in any number of counterparts, each of which shall be an original, but such counterparts shall together constitute but one and the same instrument. The exchange of copies of this Supplemental Indenture and
      of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Supplemental Indenture as to the parties hereto and may be used in lieu of the original Supplemental Indenture for all purposes. Signatures
      of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

    

    

    Section 3.07. Severability. In the
      event any provision of this Supplemental Indenture shall be invalid, illegal or unenforceable, then (to the extent permitted by law) the validity, legality or enforceability of the remaining provisions shall not in any way be affected or impaired.

    

    

    Section 3.08. Waiver of Jury Trial.
      EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS SUPPLEMENTAL INDENTURE OR THE TRANSACTIONS
      CONTEMPLATED HEREBY.

    

    

    Section 3.09. Effectiveness. This
      Supplemental Indenture shall become effective upon, without further action by the parties hereto, the effective time of the Merger.

    

    

    [Signature Page Follows]

    

    

    
      

      4

      
        

      

    

    IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the day and year first above
      written.

    

    

    	 	
            KADMON HOLDINGS, INC.

          
	 	 	 
	 	
            By:

          	
            
              /s/ Gregory Moss

            

          
	 	 	
            Name: Gregory Moss

          
	 	 	
            Title:   Executive Vice President, General Counsel

          
	 	 	 
	 	
            
              U.S. BANK NATIONAL ASSOCIATION, as Trustee

            

          
	 	 	 
	 	
            By:

          	
            
              /s/ Benjamin J. Krueger

            

          
	 	 	
            Name: Benjamin J. Krueger

          
	 	 	
            Title:   Vice President

          

    

    

    SIGNATURE PAGE TO SUPPLEMENTAL INDENTUREExhibit
4.3

 

 [NEITHER  THIS
SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS
SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES] 

 

UNDERWRITER
WARRANT TO PURCHASE AMERICAN DEPOSITARY SHARES

 

For
the Purchase of up to 

 

[●]
American Depositary Shares

Representing
[●] Ordinary Shares

of

 

Genenta
Science S.p.A.

(A
Republic of Italy Corporation)

 

Section 1. Underwriter
Warrant.

 

THIS CERTIFIES
THAT, in consideration of duly paid consideration by or on behalf of (“Holder”), as registered owner of this Underwriter
Warrant, to Genenta Science S.p.A. (“Company”), Holder is entitled to subscribe for, purchase and receive, in whole or in
part, up to [●] ([●]) American Depositary Shares (“Shares”), each Share representing one ordinary share of the
Company at any time on or after [●], 2022 (the “Commencement Date”) and on or prior to 5:00 p.m. (New York City
time) on [●], 2026 (the “Expiration Date”) but not thereafter. If the Expiration Date is a day on which banking institutions
are authorized by law to close, then this Underwriter Warrant may be exercised on the next succeeding day which is not such a day in
accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would
terminate the Underwriter Warrant. This Underwriter Warrant is initially exercisable at $[●] per share purchased (125% of the initial
public offering price per share); provided, however, that upon the occurrence of any of the events specified in Section 5 hereof,
the rights granted by this Underwriter Warrant, including the Exercise Price and the number of Shares to be received upon such exercise,
shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise
price, depending on the context.

 

Section 2. Exercise.

 

Section
2.1 Exercise Form. In order to exercise this Underwriter Warrant, the exercise form attached hereto must be duly executed and
completed and delivered to the Company, together with the Exercise Price in cash or by certified check or official bank check for the
Shares being purchased. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on
the Expiration Date, this Underwriter Warrant shall become and be void without further force or effect, and all rights represented hereby
shall cease and expire.

 

    	 

    	 

    

 

Section 2.2 Conversion
Right.

 

Section
2.2.1 Determination of Amount. In lieu of the payment of the Exercise Price in the manner required by Section 2.1, the Holder
shall have the right (but not the obligation) to convert any exercisable but unexercised portion of this Underwriter Warrant into Shares
(“Conversion Right”) as follows. Upon exercise of the Conversion Right, the Company shall deliver to the Holder (without
payment by the Holder of any of the Exercise Price in cash other than for any amount required by Italian law with respect to the nominal
equity capital contribution (imputazione a capitale sociale) of the Shares to be issued upon exercise of the Conversion Right))
that number of Shares equal to the quotient obtained by dividing (x) the “Value” (as defined below), at the close of
trading on the next to last trading day immediately preceding the exercise of the Conversion Right, of the portion of the Underwriter
Warrant being converted by (y) the “Market Price” (as defined below). The “Value” of the portion of the Underwriter
Warrant being converted shall equal the remainder derived from subtracting (a) the Exercise Price multiplied by the number of Shares
underlying that portion of this Underwriter Warrant being converted from (b) the Market Price of the Shares multiplied by the
number of Shares underlying that portion of the Underwriter Warrant being converted. As used in this herein, the term “Market Price”
at any date shall be deemed to be the average last reported sale price of the Shares for the five trading days ending on the next to
last trading day immediately preceding the exercise of the Conversion Right as officially reported by the principal securities exchange
on which the Shares are listed or admitted to trading, or, if the Shares are not listed or admitted to trading on any national securities
exchange or if any such exchange on which the Shares are listed is not its principal trading market, the average last reported sale price
for such five trading days as furnished by Nasdaq or, if applicable, the OTC Bulletin Board, or if the Shares are not listed or
admitted to trading on any of the foregoing markets, or similar organization, as determined in good faith by resolution of the Board
of Directors of the Company, based on the best information available to it. If the Shares are issued in such a cashless exercise, the
parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Shares shall take on the characteristics
of the Underwriter Warrants being exercised, and the holding period of the Shares being issued may be tacked on to the holding period
of this Underwriter Warrant. In no event will the Company be required to pay cash to the Holder to settle this Underwriter Warrant
in the event of exercise by the Holder of the Conversion Right. 

 

Section
2.2.2 Mechanics of Conversion. The Conversion Right may be exercised by the Holder on any business day on or after the Commencement
Date and not later than the Expiration Date by delivering the Underwriter Warrant with a duly executed exercise form attached hereto
with the Conversion Right section completed to the Company, exercising the Conversion Right and specifying the total number of Shares
that the Holder will purchase pursuant to such Conversion Right.

 

Section 3. Transfer.

 

Section
3.1 General Restrictions. On and after the Commencement Date, transfers by the registered Holder to others may be made subject
to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver
to the Company the assignment form attached hereto duly executed and completed, together with the Underwriter Warrant and payment of
all transfer taxes, if any, payable in connection therewith. The Company shall immediately transfer this Underwriter Warrant on the books
of the Company and shall execute and deliver a new Underwriter Warrant or Underwriter Warrants of like tenor to the appropriate assignee(s)
expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number as shall
be contemplated by any such assignment.

 

 [Section
 3.2 Restrictions Imposed by the Act. If, at the time of the surrender of this Underwriter
Warrant in connection with any transfer of this Underwriter Warrant, the transfer of this Underwriter Warrant shall not be either (i)
registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky
laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to
Rule 144, the Company may require, as a condition of allowing such transfer, this Underwriter Warrant and the Shares underlying this
Underwriter Warrant to not be transferred unless and until (a) the Company has received the opinion of counsel for the Holder that this
Underwriter Warrant or the Shares, as the case may be, may be transferred pursuant to an exemption from registration under the Securities
Act and applicable state law, the availability of which is established to the reasonable satisfaction of the Company (the Company hereby
agreeing that an opinion of Loeb & Loeb LLP shall be deemed satisfactory evidence of the availability of an exemption), or (b) a
registration statement relating to such Underwriter Warrant or Shares, as the case may be, has been filed by the Company and declared
effective by the Securities and Exchange Commission and compliance with applicable state law.] 

 

    	 

    	 

    

 

Section 4. New
Underwriter Warrants to be Issued.

 

Section
4.1 Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Underwriter Warrant may be exercised or
assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Underwriter Warrant
for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer
tax, the Company shall cause to be delivered to the Holder without charge a new Underwriter Warrant of like tenor to this Underwriter
Warrant in the name of the Holder evidencing the right of the Holder to purchase the aggregate number of Shares purchasable hereunder
as to which this Underwriter Warrant has not been exercised or assigned.

 

Section
4.2 Lost Certificate. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation
of this Underwriter Warrant and of reasonably satisfactory indemnification, and upon surrender and cancellation of the Underwriter Warrants,
if mutilated, the Company shall execute and deliver a new Underwriter Warrant of like tenor and date. Any such new Underwriter Warrant
executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation
on the part of the Company.

 

Section 5. Adjustments.

 

Section
5.1 Adjustments to Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying the Underwriter
Warrant shall be subject to adjustment from time to time as hereinafter set forth:

 

Section
5.1.1 Stock Dividends—Recapitalization, Reclassification, Split-Ups. If after the date hereof, and subject to the provisions
of Section 5.2 below, the number of outstanding Shares is increased by a stock dividend payable in Shares or by a split-up, recapitalization
or reclassification of Shares or other similar event, then, on the Commencement Date thereof, the number of Shares issuable on exercise
of the Underwriter Warrant shall be increased in proportion to such increase in outstanding Shares.

 

Section
5.1.2 Aggregation of Shares. If after the date hereof, and subject to the provisions of Section 5.2, the number of outstanding
Shares is decreased by a consolidation, combination or reclassification of Shares or other similar event, then, upon the Commencement
Date thereof, the number of Shares issuable on exercise of the Underwriter Warrant shall be decreased in proportion to such decrease
in outstanding Shares.

 

Section
5.1.3 Adjustments in Exercise Price. Whenever the number of Shares purchasable upon the exercise of this Underwriter Warrant is
adjusted, as provided in this Section 5.1, the Exercise Price shall be adjusted (to the nearest cent) by multiplying such Exercise Price
immediately prior to such adjustment by a fraction (x) the numerator of which shall be the number of Shares purchasable upon the exercise
of this Underwriter Warrant immediately prior to such adjustment, and (y) the denominator of which shall be the number of Shares so purchasable
immediately thereafter.

 

Section
5.1.4 Replacement of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding
Shares other than a change covered by Section 5.1.1 hereof or which solely affects the par value of such Shares, or in the case of any
merger or consolidation of the Company with or into another corporation (other than a consolidation or merger in which the Company is
the continuing corporation and which does not result in any reclassification or reorganization of the outstanding Shares), or in the
case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially as an
entirety in connection with which the Company is dissolved, the Holder of this Underwriter Warrant shall have the right thereafter (until
the expiration of the right of exercise of this Underwriter Warrant) to receive upon the exercise hereof, for the same aggregate Exercise
Price payable hereunder immediately prior to such event, the kind and amount of Shares or other securities or property (including cash)
receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or other
transfer, by a Holder of the number of Shares obtainable upon exercise of this Underwriter Warrant immediately prior to such event; and
if any reclassification also results in a change in Shares covered by Section 5.1.1, then such adjustment shall be made pursuant to Sections
5.1.1, 5.1.3 and this Section 5.1.4. The provisions of this Section 5.1.4 shall similarly apply to successive reclassifications, reorganizations,
mergers or consolidations, sales or other transfers.

 

    	 

    	 

    

 

Section
5.1.5 Changes in Form of Underwriter Warrant. This form of Underwriter Warrant need not be changed because of any change pursuant
to this Section, and Underwriter Warrants issued after such change may state the same Exercise Price and the same number of Shares as
are stated in the Underwriter Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new
Underwriter Warrants reflecting a required or permissive change shall not be deemed to waive any rights to a prior adjustment or the
computation thereof.

 

Section
5.2 Elimination of Fractional Interests. The Company shall not be required to issue fractions of Shares upon the exercise or transfer
of the Underwriter Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent
of the parties that all fractional interests shall be eliminated by rounding any fraction up or down to the nearest whole number of Shares.

 

Section 6. Reservation
and Listing. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of issuance
upon exercise of the Underwriter Warrants, such number of Shares or other securities, properties or rights as shall be issuable upon
the exercise thereof. The Company covenants and agrees that, upon exercise of the Underwriter Warrants and payment of the Exercise Price
therefor, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable
and not subject to preemptive rights of any stockholder. As long as the Underwriter Warrants shall be outstanding, the Company shall
use its best efforts to cause all Shares issuable upon exercise of the Underwriter Warrants to be listed (subject to official notice
of issuance) on all securities exchanges (or, if applicable on Nasdaq) on which the Shares issued to the public in connection herewith
are then listed and/or quoted.

 

Section 7. Certain
Notice Requirements.

 

Section
7.1 Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote
or consent or to receive notice as a stockholder for the election of directors or any other matter, or as having any rights whatsoever
as a stockholder of the Company. If, however, at any time prior to the expiration of the Underwriter Warrants and their exercise, any
of the events described in Section 7.2 shall occur, then, in one or more of said events, the Company shall give written notice of such
event at least fifteen (15) days prior to the date fixed as a record date or the date of closing the transfer books for the determination
of the stockholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled
to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of the
closing of the transfer books, as the case may be.

 

Section
7.2 Events Requiring Notice. The Company shall be required to give the notice described in this Section 7 upon one or more of
the following events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive
a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise than out of retained
earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, or (ii) the Company
shall offer to all the holders of its Shares any additional shares of capital stock of the Company or securities convertible into or
exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution,
liquidation or winding up of the Company (other than in connection with a consolidation or merger) or a sale of all or substantially
all of its property, assets and business shall be proposed.

 

Section
7.3 Notice of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant
to Section 7 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe
the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company’s
President and Chief Financial Officer.

 

    	 

    	 

    

 

Section
7.4 Transmittal of Notices. All notices, requests, consents and other communications under this Underwriter Warrant shall be in
writing and shall be deemed to have been duly made on the date of delivery if delivered personally or sent by overnight courier, with
acknowledgement of receipt to the party to which notice is given, or on the fifth day after mailing if mailed to the party to whom notice
is to be given, by registered or certified mail, return receipt requested, postage prepaid and properly addressed as follows: (i) if
to the registered Holder of the Underwriter Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to
the Company, to its principal executive office.

 

Section 8. Miscellaneous.

 

Section
8.1 Amendments. The Company and the underwriters may from time to time supplement or amend this Underwriter Warrant without the
approval of any of the Holders in order to cure any ambiguity, to correct or supplement any provision contained herein which may be defective
or inconsistent with any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder
which the Company and the underwriters may deem necessary or desirable and which the Company and the underwriters deem shall not adversely
affect the interest of the Holders. All other modifications or amendments shall require the written consent of the party against whom
enforcement of the modification or amendment is sought.

 

Section
8.2 Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit
or affect the meaning or interpretation of any of the terms or provisions of this Underwriter Warrant.

 

Section
8.3 Entire Agreement. This Underwriter Warrant (together with the other agreements and documents being delivered pursuant to or
in connection with this Underwriter Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter
hereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

Section
8.4 Binding Effect. This Underwriter Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the
Company and their respective successors, legal representatives and assigns, and no other person shall have or be construed to have any
legal or equitable right, remedy or claim under or in respect of or by virtue of this Underwriter Warrant or any provisions herein contained.

 

Section
8.5 Governing Law; Submission to Jurisdiction. This Underwriter Warrant shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws. The Company hereby agrees that any action, proceeding
or claim against it arising out of, or relating in any way to this Underwriter Warrant shall be brought and enforced in the courts of
the State of New York or of the United States of America for the Southern District of New York, and irrevocably submits to such jurisdiction,
which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent
an inconvenient forum. Any process or summons to be served upon the Company may be served by transmitting a copy thereof by registered
or certified mail, return receipt requested, postage prepaid, addressed to Cogency Global Inc., 122 East 42nd Street, 18th Floor, New
York, New York 10168. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding
or claim. The Company and the Holder, by acceptance hereof, agree that the prevailing party(ies) in any such action shall be entitled
to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or
incurred in connection with the preparation therefor.

 

Section
8.6 Waiver, Etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Underwriter Warrant
shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Underwriter Warrant
or any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Underwriter
Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Underwriter Warrant shall be effective
unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought;
and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent
breach, non-compliance or non-fulfillment.

 

    	 

    	 

    

 

 [Section
9. Registration Rights. 

   

 Section
9.1 Demand Registration. 

   

 Section
9.1.1 Grant of Right. The Company, upon written demand (“Initial Demand Notice”) of the Holder(s) of 50% or more of
the underlying Shares (“Majority Holders”), agrees to register on one occasion, all or any portion of this Underwriter Warrant
and all of the Shares underlying this Underwriter Warrant (collectively the “Registrable Securities”). On such occasion,
the Company will file a registration statement covering the Registrable Securities within sixty (60) days after receipt of the Initial
Demand Notice and use its best efforts to have the registration statement declared effective promptly thereafter. If the Company fails
to comply with the provisions of this Section 9.1.1, the Company shall, in addition to any other equitable or other relief available
to the Holder(s), be liable for any and all damages sustained by the Holder(s) as described in Section 9.3.6. The demand for registration
may be made at any time during a period of four years beginning one year from the Effective Date. The Company covenants and agrees to
give written notice of its receipt of any Initial Demand Notice by any Holder(s) to all other registered Holders of this Underwriter
Warrant and/or the Registrable Securities within ten days from the date of the receipt of any such Initial Demand Notice. 

   

 Section
9.1.2 Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities, but the Holders
shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection
with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts to cause the filing required herein
to become effective promptly and to qualify or register the Registrable Securities in such States as are reasonably requested by the
Holder(s); provided, however, that in no event shall the Company be required to register the Registrable Securities in a State
in which such registration would cause the Company to be obligated to register or license to do business in such State or submit to general
service of process in such State. The Company shall cause any registration statement filed pursuant to the demand right granted under
Section 9.1.1 to remain effective for a period of at least six consecutive months from the date that the Holders of the Registrable Securities
covered by such registration statement are first given the opportunity to sell all of such securities. 

   

 Section
9.2 “Piggy-Back” Registration. 

   

 Section
9.2.1 Grant of Right. In addition to the demand right of registration, the Holders of this Underwriter Warrant shall have the
right for a period of six (6) years commencing one year from the Effective Date, to include the Registrable Securities as part of any
other registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated
under the Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, in the written determination of the
Company’s managing underwriter or underwriters, if any, for such offering, the inclusion of the Registrable Securities, when added
to the securities being registered by the Company or the selling stockholder(s), will exceed the maximum amount of the Company’s
securities which can be marketed (i) at a price reasonably related to their then current market value, or (ii) without materially and
adversely affecting the entire offering, the Company will include in such registration (a) first, the Securities the Company proposes
to sell and (b) second, any other securities registered on behalf of selling stockholders, including the Holders, pro rata among such
stockholders on the basis of the number of securities requested by such stockholders to be included. 

   

 Section
9.2.2 Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities, but the Holders
shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection
with the sale of the Registrable Securities. In the event of such a proposed registration, the Company shall furnish the then Holders
of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date of filing of such
registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until
such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable Securities shall exercise
the “piggy-back” rights provided for herein by giving written notice, within twenty (20) days of the receipt of the Company’s
notice of its intention to file a registration statement. The Company shall cause any registration statement filed pursuant to the above
“piggyback” rights to remain effective for at least six months from the date that the Holders of the Registrable Securities
are first given the opportunity to sell all of such securities. 

   

    	 

    	 

    

   

 Section
9.3 General Terms. 

   

 Section
9.3.1 Indemnification. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration
statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Act or Section 20(a) of
the Securities Exchange Act of 1934, as amended (“Exchange Act”), against all loss, claim, damage, expense or liability (including
all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim
whatsoever) to which any of them may become subject under the Act, the Exchange Act or otherwise, arising from such registration statement
but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Underwriters
contained in Section 5 of the Underwriting Agreement between the Underwriters and the Company, dated the Effective Date. The Holder(s)
of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally,
and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including all reasonable attorneys’
fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may
become subject under the Act, the Exchange Act or otherwise, arising from information furnished by or on behalf of such Holders, or their
successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect
as the provisions contained in Section 5 of the Underwriting Agreement pursuant to which the Underwriters have agreed to indemnify the
Company. 

   

 Section
9.3.2 Exercise of this Underwriter Warrant. Nothing contained in this Underwriter Warrant shall be construed as requiring the
Holder(s) to exercise this Underwriter Warrant prior to or after the initial filing of any registration statement or the effectiveness
thereof. 

   

 Section
9.3.3 Documents Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings
and to each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of (i) an opinion
of counsel to the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten
public offering, an opinion dated the date of the closing under any underwriting agreement related thereto) relating to, among other
matters, the due establishment of the Company, the validity of the shares being issued and the due execution and delivery of the underwriting
agreement and a statement of such counsel regarding the absence of material misstatements or omissions in such registration statement,
and (ii) a “cold comfort” letter dated the effective date of such registration statement (and, if such registration includes
an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent public
accountants who have issued a report on the Company’s financial statements included in such registration statement covering substantially
the same matters with respect to such registration statement (and the prospectus included therein) and with respect to events subsequent
to the date of such financial statements as are customarily covered in accountants’ letters delivered to underwriters in underwritten
public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering requesting the correspondence
described below and to the managing underwriter copies of all correspondence between the Commission and the Company, its counsel or auditors
and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each
Holder and underwriter to do such investigation, upon reasonable advance notice, with respect to information contained in or omitted
from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation
shall include access to books, records and properties and opportunities to discuss the business of the Company with its officers and
independent auditors, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request. 

   

    	 

    	 

    

   

 Section
9.3.4 Underwriting Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s) selected
by any Holders whose Registrable Securities are being registered pursuant to this Section 9, which managing underwriter shall be reasonably
satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each Holder and such
managing underwriters, and shall contain such representations, warranties and covenants by the Company and such other terms as are customarily
contained in agreements of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating
to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the representations, warranties
and covenants of the Company to or for the benefit of such underwriters shall also be made to and for the benefit of such Holders. Such
Holders shall not be required to make any representations or warranties to or agreements with the Company or the underwriters except
as they may relate to such Holders, their Shares and their intended methods of distribution. 

   

 Section
9.3.5 Documents to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish
to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling securityholders. 

   

 Section
9.3.6 Damages. Should the registration or the effectiveness thereof required by Sections 9.1 and 9.2 hereof be delayed by the
Company or the Company otherwise fails to comply with such provisions, the Company shall, in addition to any other equitable or other
relief available to the Holder(s), be liable for any and all damages sustained by the Holder(s), including, but not limited to, the loss
of any profits that might have been received by the Holder upon the sale of Shares underlying this Underwriter Warrant. 

 

    	 

    	 

    

 

IN WITNESS
WHEREOF, the Company has caused this Underwriter Warrant to be signed by its duly authorized officer as of the day of [●], 2021.

 

	 	GENENTA SCIENCE
    S.P.A.
	 	 
	 	By:	
	 	 	Pierluigi Paracchi 
	 	 	Chief Executive Officer

 

    	 

    	 

    

 

Form to be
used to exercise Underwriter Warrant:

 

Genenta Science
S.p.A.

 

Date:

 

The undersigned
hereby elects irrevocably to exercise the within Underwriter Warrant and to purchase Shares of Genenta Science S.p.A. and hereby makes
payment of $ (at the rate of $ per share) in payment of the Exercise Price pursuant thereto. Please issue the Share as to which this
Underwriter Warrant is exercised in accordance with the instructions given below.

 

or

 

The undersigned
hereby elects irrevocably to exercise the within Underwriter Warrant and to purchase Shares of Genenta Science S.p.A. by surrender of
the unexercised portion of the within Underwriter Warrant (with a “Value” of $   based on a “Market Price”
of $  ). Please issue the Shares as to which this Underwriter Warrant is exercised in accordance with the instructions given below.

 

	 	
	 	Signature

 

NOTICE: The
signature to this form must correspond with the name as written upon the face of the within Underwriter Warrant in every particular without
alteration or enlargement or any change whatsoever.

 

INSTRUCTIONS FOR REGISTRATION OF SECURITIES 

 

	Name	 	
	 	 	(Print
    in Block Letters)
	 	 	 
	Address	 	 

 

    	 

    	 

    

 

Form to be
used to assign Underwriter Warrant:

 

ASSIGNMENT

 

(To be executed
by the registered Holder to effect a transfer of the within Underwriter Warrant):

 

FOR VALUE RECEIVED,
does hereby sell, assign and transfer unto the right to purchase Shares of Genenta Science S.p.A. (“Company”) evidenced by
the within Underwriter Warrant and does hereby authorize the Company to transfer such right on the books of the Company.

 

Dated:

 

	 	 	
	 	 	Signature
	 	 	 
		 	 
	Signature Guaranteed	 	 

 

NOTICE: The
signature to this form must correspond with the name as written upon the face of the within Underwriter Warrant in every particular without
alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company
or by a firm having membership on a registered national securities exchange.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]